仅供临床科研使用
Secondary Dose Check 了解更多
销售价格： ￥ N/A
商品编号： SP-295-0851
软件语言： 英文
器械分类： II
生产厂家： DOSIsoft SA
公司网址： https://www.dosisoft.com/
认证信息： FDA
系统要求： Windows
交付方式： 下载安装
  • 软件概览
  • 推荐配置
  • 典型病例
  • 软件教程
  • 临床文献
  • 用户评价
  • 产品彩页

软件概览

Fast, reliable and independent 3D dose calculation for adaptive radiotherapy workflows

Using a fully independent and innovative Collapsed Cone Convolution algorithm, ThinkQA Secondary Dose Check is designed to verify if the dose distribution calculated by a Treatment Planning System (TPS) for External Beam Radiation Therapy (EBRT) is consistent with treatment plan parameters. It helps Radiation Therapy centers meet reporting and reimbursement needs, ensure compliance in plan quality and gain confidence in patient safety.

Compatible with linear accelerators, it has been specifically adapted to MR-Linac, supporting beam specificities and adaptive workflow.

Through its ergonomic web dashboard, the user can not only access full dose matrix analysis including automatic volume indicators, and Gamma Passing Rates, but also receive automatic report and perform approval action.


Designed for online adaptive workflows

· DICOM import of RT structure set, RT plan, RT dose and CT image series

· Automatic dose calculation once plan data receipt

· Full web interface with plan verification summary and advanced graphics

· Export session of treatment reports to OIS


Automatic 3D dose distribution comparison

· Superimposition of full dose matrix differential DVH (TPS and ThinkQA dose values)

· DVHs comparison and DVHs deviations (d2, d50, d90, d95, d98)

· Four automatic volumes (High dose, High gradient, Mean dose and Low dose)

· Gamma Index histogram for PTVs, OARs and automatic volumes

· Gamma Passing Rate: Alerts based on 3D γ Agreement Index for PTVs and High dose volume


Fast Plan Verification

· Fast & independent Collapsed Cone Convolution (CCC) algorithm with CPU parallelization

· Whole dose distribution comparison results are provided within minutes

· Automatic alerts in case plans fail to pass user-defined tolerance thresholds


User-friendly, web-based interface

· Color-coded treatment plan verification outcome for each plan

· Configurable approval actions (Accept, Reject and Ignore)

· Treatment QA timeline insights per patient with primary and adaptive plans


Unique Dose Calculation adapted to Elekta Unity

· Independent Collapsed Cone Convolution (CCC) algorithm

· Beam model adapted to 7 MV FFF Elekta Unity beam with 3D wrapped point kernel in a 1.5T magnetic field

· Includes patient couch and coils components

· Editable cryostat transmission map

· Ready-to-use beam model template for easy commissioning


* Product distributed exclusively by Elekta




推荐配置


典型病例


软件教程


临床文献

Commissioning of Commercial Secondary Dose Check Software and Clinical Implementation for the Magnetic Resonance-guided Linear Accelerator Adaptive Workflow


ABSTRACT

Purpose: The purpose of this study was to report the commissioning the secondary dose calculation software ThinkQA (TQA) for an magnetic resonance‑guided linear accelerator (MR‑linac). 

 
Methods: The Medical Physics Practice Guideline 5.a. (MPPG5a) tests, and dose in inhomogeneities, beam profiles, and depth dose curves were calculated and compared between Monaco and TQA. Five intensity modulated radiotherapy (IMRT) plans (anal, abdominal, head and neck, prostate, and lung), based on TG‐244 guidelines were evaluated varying the gamma criteria. Furthermore, the initial and adapted plans for the first session for 17 patients in different anatomical regions were calculated in TQA using different gamma criteria. For five patients, six measurements were made at different fractions using ArcCheck and compared with TQA.

Results: The majority of tests met the tolerances defined in the MPPG5a with the exception of dose profiles (>10%), and large multileaf collimator‑shaped fields with extensive blocking (>2%). For the IMRT plans, tight criteria such as 2%/2 mm may not be suitable for all scenarios. Thus, we adopt a reasonable 3%/2 mm without compromising the quality of the plan that included significant high‑to‑low‑density interfaces. It is observed that, the values obtained for clinical cases are in the range from 94.6% to 99.8% (TQA), 97.0% to 99.6% (ArcCheck), except in a prostate case with 87.8% (TQA) and 99.3% (ArcCheck). 

Conclusion: We commissioned TQA as a secondary dose calculation for MR‑linac and we introduced it clinically for adaptive treatment workflow using 3%/2 mm with 95% as tolerance limit and 90% as action limit.

Download the complete article

用户评价


产品彩页


请完善个人信息

非常抱歉，您只有购买软件后才能查看完整软件教程！

看了此商品的会员还在看
测试版
版本号 软件大小 下载地址
01 1m 下载
正式版
版本号 软件大小 下载地址
01 1m 下载